A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease
← catalyst calendarSponsored by Palisade Bio (industry) · PALI — their whole pipeline →. With Altasciences Company Inc..
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
6estimated
Sites
1
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-17 | actual | When the study began enrolling |
| Primary completion | 2026-01-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-15 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Fibrostenotic Crohn's Disease
Intervention
- Drug: PALI-2108
Primary outcomes
what the primary-completion date above is the date OFSafety and tolerability of PALI-2108 administered for 14 days.
measured 14 days
Safety and tolerability of PALI-2108
measured 14 Days
Safety and tolerability of PALI-2108
measured 14 Days
Safety and tolerability of PALI-2108
measured 14 Days
Permalink · PALI's whole pipeline · Catalyst calendar · Every registered study · What changed